Clinical characteristics of HNF1B-related disorders in a Japanese population.


Journal

Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 28 02 2019
accepted: 07 05 2019
pubmed: 28 5 2019
medline: 11 2 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

Hepatocyte nuclear factor 1β (HNF1B), located on chromosome 17q12, causes renal cysts and diabetes syndrome (RCAD). Moreover, various phenotypes related to congenital anomalies of the kidney and urinary tract (CAKUT) or Bartter-like electrolyte abnormalities can be caused by HNF1B variants. In addition, 17q12 deletion syndrome presents with multi-system disorders, as well as RCAD. As HNF1B mutations are associated with different phenotypes and genotype-phenotype relationships remain unclear, here, we extensively studied these mutations in Japan. We performed genetic screening of RCAD, CAKUT, and Bartter-like syndrome cases. Heterozygous variants or whole-gene deletions in HNF1B were detected in 33 cases (19 and 14, respectively). All deletion cases were diagnosed as 17q12 deletion syndrome, confirmed by multiplex ligation probe amplification and/or array comparative genomic hybridization. A retrospective review of clinical data was also conducted. Most cases had morphological abnormalities in the renal-urinary tract system. Diabetes developed in 12 cases (38.7%). Hyperuricemia and hypomagnesemia were associated with six (19.3%) and 13 cases (41.9%), respectively. Pancreatic malformations were detected in seven cases (22.6%). Ten patients (32.3%) had liver abnormalities. Estimated glomerular filtration rates were significantly lower in the patients with heterozygous variants compared to those in patients harboring the deletion (median 37.6 vs 58.8 ml/min/1.73 m We present the clinical characteristics of HNF1B-related disorders. To predict renal prognosis and complications, accurate genetic diagnosis is important. Genetic testing for HNF1B mutations should be considered for patients with renal malformations, especially when associated with other organ involvement.

Sections du résumé

BACKGROUND BACKGROUND
Hepatocyte nuclear factor 1β (HNF1B), located on chromosome 17q12, causes renal cysts and diabetes syndrome (RCAD). Moreover, various phenotypes related to congenital anomalies of the kidney and urinary tract (CAKUT) or Bartter-like electrolyte abnormalities can be caused by HNF1B variants. In addition, 17q12 deletion syndrome presents with multi-system disorders, as well as RCAD. As HNF1B mutations are associated with different phenotypes and genotype-phenotype relationships remain unclear, here, we extensively studied these mutations in Japan.
METHODS METHODS
We performed genetic screening of RCAD, CAKUT, and Bartter-like syndrome cases. Heterozygous variants or whole-gene deletions in HNF1B were detected in 33 cases (19 and 14, respectively). All deletion cases were diagnosed as 17q12 deletion syndrome, confirmed by multiplex ligation probe amplification and/or array comparative genomic hybridization. A retrospective review of clinical data was also conducted.
RESULTS RESULTS
Most cases had morphological abnormalities in the renal-urinary tract system. Diabetes developed in 12 cases (38.7%). Hyperuricemia and hypomagnesemia were associated with six (19.3%) and 13 cases (41.9%), respectively. Pancreatic malformations were detected in seven cases (22.6%). Ten patients (32.3%) had liver abnormalities. Estimated glomerular filtration rates were significantly lower in the patients with heterozygous variants compared to those in patients harboring the deletion (median 37.6 vs 58.8 ml/min/1.73 m
CONCLUSION CONCLUSIONS
We present the clinical characteristics of HNF1B-related disorders. To predict renal prognosis and complications, accurate genetic diagnosis is important. Genetic testing for HNF1B mutations should be considered for patients with renal malformations, especially when associated with other organ involvement.

Identifiants

pubmed: 31131422
doi: 10.1007/s10157-019-01747-0
pii: 10.1007/s10157-019-01747-0
doi:

Substances chimiques

HNF1B protein, human 0
Hepatocyte Nuclear Factor 1-beta 138674-15-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1119-1129

Subventions

Organisme : The Health Labor Sciences Research Grant
ID : H24-nanchi-ippan-041
Organisme : The Health Labor Sciences Research Grant
ID : H29-nanchi-ippan-039
Organisme : Japan Society for the Promotion of Science
ID : 15K09261
Organisme : Japan Society for the Promotion of Science
ID : 18K08243

Références

J Mol Endocrinol. 2001 Aug;27(1):11-29
pubmed: 11463573
J Am Soc Nephrol. 2003 Aug;14(8):2033-41
pubmed: 12874457
EMBO J. 2004 Apr 7;23(7):1657-68
pubmed: 15029248
Ann Intern Med. 2004 Apr 6;140(7):510-7
pubmed: 15068978
J Med Genet. 2006 Jan;43(1):84-90
pubmed: 15930087
Kidney Int. 2005 Nov;68(5):1944-7
pubmed: 16221171
Nat Genet. 2006 Jan;38(1):21-3
pubmed: 16341222
Hum Mol Genet. 2006 Aug 1;15(15):2363-75
pubmed: 16801329
Diabetologia. 2008 Apr;51(4):546-53
pubmed: 18297260
J Am Soc Nephrol. 2009 May;20(5):1123-31
pubmed: 19389850
Clin J Am Soc Nephrol. 2010 Jun;5(6):1079-90
pubmed: 20378641
Clin J Am Soc Nephrol. 2013 Jul;8(7):1179-87
pubmed: 23539225
Kidney Int. 2014 Nov;86(5):1007-15
pubmed: 24897035
Nat Rev Nephrol. 2015 Feb;11(2):102-12
pubmed: 25536396
Pediatr Nephrol. 2016 May;31(5):707-14
pubmed: 26160100
J Am Soc Nephrol. 2016 Feb;27(2):345-53
pubmed: 26319241
Pediatr Transplant. 2016 May;20(3):467-71
pubmed: 26899772
Diabetes Obes Metab. 2016 Sep;18 Suppl 1:23-32
pubmed: 27615128
Diabetes Care. 2017 Nov;40(11):1436-1443
pubmed: 28420700
Clin Exp Nephrol. 2018 Aug;22(4):881-888
pubmed: 29372472
J Diabetes Investig. 2019 Jul;10(4):1112-1115
pubmed: 30637974
Pediatr Nephrol. 2019 Aug;34(8):1457-1464
pubmed: 30937553

Auteurs

China Nagano (C)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Naoya Morisada (N)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. morisada@med.kobe-u.ac.jp.
Department of Clinical Genetics, Hyogo Prefectural Kobe Children's Hospital, 1-6-7, Minatojimaminami-machi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. morisada@med.kobe-u.ac.jp.

Kandai Nozu (K)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Koichi Kamei (K)

Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.

Ryojiro Tanaka (R)

Department of Nephrology, Hyogo Prefectural Kobe Children's Hospital, 1-6-7 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.

Shoichiro Kanda (S)

Department of Pediatrics, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Shinichi Shiona (S)

Department of Pediatrics, Oita Prefectural Hospital, 476, Oaza-Bujyo, Oita, Oita, 870-8511, Japan.

Yoshinori Araki (Y)

Department of Pediatrics, Hokkaido Medical Center, 5-7-1-1 Yamanote Nishi-ku, Sapporo, Hokkaido, 063-0005, Japan.

Shinichiro Ohara (S)

Department of Pediatrics, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima-shi, Fukushima, 960-1295, Japan.

Chieko Matsumura (C)

Department of Pediatrics, National Hospital Organization Chibahigashi National Hospital, 673 Nitonacho, Chuo-ku, Chiba, Chiba, 260-8712, Japan.

Katsuaki Kasahara (K)

Department of Pediatric Nephrology, Japanese Red Cross Nagoya Daini Hospital, 2-9 Myokencho, Syowa-ku, Nagoya, 4668-650, Japan.

Yukiko Mori (Y)

Department of Pediatrics, Japanese Red Cross Fukui Hospital, 2-4-1, Tsukimi, Fukui, 918-8501, Japan.

Akane Seo (A)

Department of Diabetes and Endocrinology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.

Kenichiro Miura (K)

Department of Pediatric Nephrology, Tokyo Women's Medical University, School of Medicine, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Miki Washiyama (M)

Department of Diabetes and Endocrinology, Kusatsu General Hospital, 1660 Yabase-cho, Kusatsu, Siga, 525-8585, Japan.

Keisuke Sugimoto (K)

Department of Pediatrics, Faculty of Medicine, Kindai University, 377-2, Ohno-Higashi, Osakasayama, Osaka, 589-8511, Japan.

Ryoko Harada (R)

Department of Nephrology, Tokyo Metropolitan Children's Medical Center, 2-8-29, Musashidai, Fuchu, Tokyo, 183-8561, Japan.

Satoshi Tazoe (S)

Department of Metabolism, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-ku, Osaka, 534-0021, Japan.

Hiroyo Kourakata (H)

Department of Respiratory Medicine, Niigata Saiseikai Sanjo Hospital, 6-18 Oonohata, Sanjyo-shi, Niigata, 955-8511, Japan.

Mayumi Enseki (M)

Department of Pediatrics, Tokai University Hospital, 143, Shimokasuya, Isehara-shi, Tokyo, 259-1193, Japan.

Daisuke Aotani (D)

Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences and Medical School, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.

Takeshi Yamada (T)

Department of Pediatrics, Niigata University School of Medicine, 1-757, Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

Nana Sakakibara (N)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Tomohiko Yamamura (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Shogo Minamikawa (S)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Kenji Ishikura (K)

Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Department of Pediatrics, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara, 252-0375, Japan.

Shuichi Ito (S)

Department of Pediatrics, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

Motoshi Hattori (M)

Department of Pediatric Nephrology, Tokyo Women's Medical University, School of Medicine, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Kazumoto Iijima (K)

Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH